OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr DeBernardo on the Use of Later-Line Maintenance Therapy in Ovarian Cancer

February 16th 2024

Robert DeBernardo, MD, discusses the use of maintenance therapy in the second- and later-line settings for patients with ovarian cancer.

Dr Shreve on the Potential Impact and Utility of AI in Cancer Care

February 16th 2024

Jacob Shreve, MD, discusses the potential impact of implementing artificial intelligence into cancer care.

Dr Tripathi on the NEMIO Trial of Durvalumab Plus Chemo With/Without Tremelimumab in MIBC

February 16th 2024

Abhishek Tripathi, MD, discusses the phase 1/2 NEMIO trial of durvalumab/chemotherapy with/without tremelimumab in muscle-invasive bladder cancer.

Dr Advani on the Evaluation of Ribociclib/Endocrine Therapy in HR+/HER2– Breast Cancer

February 16th 2024

Pooja Advani, MBBS, MD, discusses the use of ribociclib plus endocrine therapy for patients with hormone receptor–positive, HER2– breast cancer.

Dr Shore on the Implications of the FDA Approval of Enzalutamide for nmCSPC

February 16th 2024

Neal Shore, MD, FACS, discusses the implications of the FDA approval of enzalutamide for patients with nonmetastatic castration-sensitive prostate cancer.

Dr Appel on the Significance of International Childhood Cancer Day

February 15th 2024

Burton Eliot Appel, MD, discusses the significance of International Childhood Cancer Day.

Dr Shore on the Background and Outcomes of the EMBARK Trial in nmCSPC

February 15th 2024

Neal Shore, MD, FACS, discusses the phase 3 EMBARK study of enzalutamide in patients with nonmetastatic castration-sensitive prostate cancer.

Dr Mikhael on Research Developments in Multiple Myeloma

February 15th 2024

Joseph Mikhael, MD, discusses treatment advancements and ongoing research in multiple myeloma.

Dr Choi on the Implications of Approving Liso-Cel in Patients With CLL

February 15th 2024

Michael Choi, MD, discusses the potential FDA approval of lisocabtagene maraleucel in patients with relapsed/refractory chronic lymphocytic leukemia.

Dr McAndrew on the HER2CLIMB-02 Trial in HER2+ Breast Cancer

February 15th 2024

Nicholas P. McAndrew, MD, MSCE, discusses the phase 3 HER2CLIMB-02 trial of tucatinib plus trastuzumab emtansine in HER2-positive early breast cancer.

Dr Nguyen on Trimodal Therapy in MIBC

February 15th 2024

Anthony T. Nguyen, MD, PhD, discusses the methodology of trimodal therapy in patients with muscle-invasive bladder cancer.

Dr Dotan on the Use of Geriatric Assessments to Identify Unique Challenges in GI Cancer

February 15th 2024

Efrat Dotan, MD, discusses the use of geriatric function assessments in elderly patients with gastroesophageal cancer.

Dr Zhang on the Implications of Findings From the KEYNOTE-564 Trial in RCC

February 14th 2024

Tian Zhang, MD, MHS, discusses the implications of subgroup analyses from the KEYNOTE-564 trial in patients with renal cell carcinoma.

Dr Hagensee on Strategies For Cervical Cancer Prevention

February 14th 2024

Michael Hagensee, MD, PhD, discusses strategies for cervical cancer prevention and ongoing research investigating barriers to cervical cancer treatment.

Dr Cohen on Available Treatments For MCL

February 14th 2024

Jonathon B. Cohen, MD, MS, discusses the background of the BRUIN study of pirtobrutinib in previously treated patients with mantle cell lymphoma.

Dr Parrondo on the RedirecTT-1 Trial of Teclistamab Plus Talquetamab in Multiple Myeloma

February 14th 2024

Ricardo D. Parrondo, MD, discusses the phase 1b/2 RedirecTT-1 of teclistamab and talquetamab in relapsed/refractory multiple myeloma.

Dr Advani on the Advantages of Liquid Biopsy in Metastatic Breast Cancer

February 14th 2024

Pooja Advani, MBBS, MD, discusses the advantages of using liquid biopsy in metastatic breast cancer.

Dr Tripathi on the Use of Frontline Nivolumab/Chemotherapy in Urothelial Carcinoma

February 13th 2024

Abhishek Tripathi, MD, discusses the significance of data from the phase 3 CheckMate 901 trial in metastatic or unresectable urothelial carcinoma.

Dr Nathan on the Significance of Tebentafusp in HLA-A*02:01+ Uveal Melanoma

February 13th 2024

Paul D. Nathan, MBBS, PhD, FRCP, discusses the clinical significance of updated data on tebentafusp in metastatic uveal melanoma.

Dr Kim on the Background of a Real-World Study of the Use of Regorafenib in mCRC

February 13th 2024

Richard Kim, MD, discusses a real-world investigation of long-term responses with regorafenib in metastatic colorectal cancer.